Cargando…

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma

Belantamab mafodotin (belamaf) is an antibody–drug conjugate (ADC) targeting B‐cell maturation antigen (BCMA). Nonlinear mixed‐effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), and cysteine‐maleimidocaproyl‐MMAF (cys‐mcMMAF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rathi, Chetan, Collins, Jon, Struemper, Herbert, Opalinska, Joanna, Jewell, Roxanne C., Ferron‐Brady, Geraldine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376139/ https://www.ncbi.nlm.nih.gov/pubmed/34076364 http://dx.doi.org/10.1002/psp4.12660

Ejemplares similares

Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma
por: Ferron‐Brady, Geraldine, et al.
Publicado: (2021)

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
por: Collins, Jon, et al.
Publicado: (2023)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
por: Becnel, Melody R., et al.
Publicado: (2020)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
por: Richardson, Paul G., et al.
Publicado: (2020)

Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
por: Iida, Shinsuke, et al.
Publicado: (2023)

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
por: Wahab, Ahsan, et al.
Publicado: (2021)

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14
por: Hultcrantz, M., et al.
Publicado: (2022)

P20: POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Iula, R, et al.
Publicado: (2022)

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM ANALYSIS
por: Quach, H., et al.
Publicado: (2022)

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma
por: Popat, Rakesh, et al.
Publicado: (2023)

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
por: Nooka, A., et al.
Publicado: (2023)

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN
por: Munawar, U., et al.
Publicado: (2023)

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
por: Springer, Carsten, et al.
Publicado: (2023)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
por: Shah, Anshul, et al.
Publicado: (2021)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
por: Joseph, Nisha S, et al.
Publicado: (2021)

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma
por: Ketchum, Emily Behren, et al.
Publicado: (2022)

Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
por: Shragai, Tamir, et al.
Publicado: (2022)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
por: de la Rubia, Javier, et al.
Publicado: (2023)

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE
por: Hultcrantz, Malin, et al.
Publicado: (2023)

P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lowther, D.E., et al.
Publicado: (2023)

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY
por: Suvannasankha, A., et al.
Publicado: (2022)

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
por: Neupane, Karun, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
por: Prawitz, Thibaud, et al.
Publicado: (2021)

P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY
por: Roussel, M., et al.
Publicado: (2023)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)

Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
por: Gil-Sierra, Manuel David, et al.
Publicado: (2022)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
por: Vaxman, I., et al.
Publicado: (2021)

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
por: Lonial, Sagar, et al.
Publicado: (2021)

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
por: Popat, R, et al.
Publicado: (2022)

Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
por: Alegre, Adrián, et al.
Publicado: (2022)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Chari, Ajai, et al.
Publicado: (2023)

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
por: Iula, Rossella, et al.
Publicado: (2022)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, Efstathios, et al.
Publicado: (2023)

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin
por: Lu, Rebecca, et al.
Publicado: (2023)

S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)
por: Dimopoulos, Meletios A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ku4r9b03u150868fmfmff6trpc